Skip to main content
OpenTrials
Completed

NCT Number: NCT05148988

Ultrasound Velocimetry in the Abdominal Aorta Before and After Endovascular Aneurysm Repair

Rationale: An abdominal aortic aneurysm (AAA) is a common vascular disease with a high mortality in case of rupture. The underlying processes initiating aneurysmal degeneration and driving aneurysmal growth remain poorly understood. Local hemodynamics might play a key role in the pathogenesis of AAA, as it is associated with aneurysmal growth, intraluminal thrombus formation and rupture risk. Visualizing and quantifying local blood flow profiles could eventually provide more insight in the underlying mechanisms of aneurysm progression as well as identify smaller AAA with increased vulnerability or larger AAA with low risk of rupture. Consequently, this may improve risk assessment and provide patient-specific therapy guidance. Nowadays, endovascular aneurysm repair (EVAR) is the preferred treatment modality in most patients with an infrarenal AAA. However, EVAR is associated with a relatively high reintervention rate. It is hypothesized that the placement of a stent graft may alter local hemodynamics and subsequent recirculations or flow stagnations promote the onset of thrombosis or micro-emboli. These unfavourable flow conditions might be related to various complications after EVAR, such as limb occlusion, renal dysfunction, and the persistence of type II endoleaks. Visualizing local blood flow profiles after EVAR might provide insight in these (un)favourable conditions. In vivo blood flow quantification is a great challenge, particularly in the abdomen. Advanced ultrasound based techniques, incorporating ultrasound contrast agents and plane wave imaging, proved to be feasible in quantifying aortoiliac blood flow patterns in healthy volunteers.

Objective: The aim of this study is to determine the feasibility of ultrafast contrast-enhanced ultrasound particle image velocimetry (echoPIV) measurements to quantify spatiotemporal blood flow velocity profiles in the abdominal aorta of AAA patients before and after endovascular repair.

Secondary objectives are to determine the correlation between echoPIV and phase-contrast MRI (PC MRI) based measurements to ultimately validate the spatiotemporal velocity profiles obtained with echoPIV. Furthermore, changes in blood flow velocity profiles after placement of a stent graft will be evaluated.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Rijnstate Hospital

Arnhem, Netherlands

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female > 18 years of age
  • BMI ≤ 30 kg/m2
  • Infrarenal AAA
  • Scheduled for elective EVAR with the Endurant II stent graft
  • Informed consent form understood and signed, and agrees to all visits

Exclusion criteria

  • Hypersensitivity to the active substance(s) or any of the excipients in Sonovue
  • Right-to-left cardiac shunt
  • Severe pulmonary hypertension (pulmonary artery pressure > 90mmHg)
  • Uncontrolled systemic hypertension
  • Severe pulmonary disease (e.g. COPD GOLD 3 or 4, adult respiratory distress syndrome)
  • Clinically unstable cardiac disease (recent, < 3 months, or ongoing myocardial infarction, unstable angina at rest, recent percutaneous coronary intervention, clinically worsening cardiac symptoms, severe cardiac arrhythmia's, endocarditis, etc.)
  • Prosthetic valves
  • Loss of renal function (GFR < 31 ml/min), end-stage renal disease
  • End-stage liver disease
  • Sepsis
  • Hypercoagulable status, recent (< 3 months) thrombosis
  • Congestive heart failure (class III or IV)
  • Pregnancy
  • MRI exclusion criteria (pacemakers, cerebral vascular clips, claustrophobia)

Treatment and study plan

EchoPIV

Diagnostic Test

All patients will undergo an echoPIV measurement 6 to 8 weeks before and 6 to 8 weeks after endovascular aneurysm repair. These measurements will take place at the Vascular Center of Rijnstate Hospital. A venous cannula will be inserted to enable contrast administration. Ultrasound data will be collected at the caudal renal artery, infrarenal neck, aneurysm sac and both iliac arteries.

4D flow MRI

Diagnostic Test

A 4D phase-contrast magnetic resonance imaging (4D flow MRI) scan of the abdominal aorta will be obtained 6 to 8 weeks before and 6 to 8 weeks after endovascular aneurysm repair.

Primary outcomes

  1. Qualitative assessment vector velocity fields

    Time frame: 6 to 8 weeks after the procedure (endovascular repair)

    Vector velocity fields derived from the echoPIV data will be used to calculate and visualize the velocity profile. In order to answer the question regarding feasibility of echoPIV the quality of the vector velocity fields will be assessed using three different metrics of which the first one is a qualitative assessment by different observers. Recordings of the contrast-enhanced ultrasound with an overlay of the vector velocity profiles will be reviewed on different topics following a scoring rubrics.

  2. Contrast-to-background ratio

    Time frame: 6 to 8 weeks after the procedure (endovascular repair)

    The contrast-to-background ratio (CBR) is the second metric to assess the outcomes of the echoPIV measurements. The CBR is a quantitative measure for the contrast levels and therefore for the quality of the contrast-enhanced US image. The higher the CBR level (in dB) the higher the intensity of the contrast which is needed for sufficient PIV analysis.

  3. Vector correlation

    Time frame: 6 to 8 weeks after the procedure (endovascular repair)

    The vector correlation is the third metric to assess the outcomes of the echoPIV measurements. The vector correlation demonstrates the tracking performance of the PIV algorithm. The vector correlation provides a unitless value between 0 and 1 in which 0 indicates poor tracking of the microbubble contrast and 1 indicates perfect tracking of the microbubble contrast.

Secondary outcomes

  1. Correlation echoPIV and 4D flow MRI

    Time frame: 6 to 8 weeks after the procedure (endovascular repair)

    EchoPIV derived local hemodynamics will be compared to outcomes of the 4D flow MRI scan.

  2. Influence of stent-graft placement

    Time frame: 6 to 8 weeks after the procedure (endovascular repair)

    EchoPIV derived local hemodynamics prior to- and after placement of the stent-graft will be compared.

  3. Vorticity

    Time frame: 6 to 8 weeks after the procedure (endovascular repair)

    Multiple blood flow parameters will be derived from the echoPIV data. The first one is the vorticity, or the curl of the velocity. The vorticity represents the rotation of particles inside the flow field. This measure can potentially be used to define regions with disturbed blood flow, as a high value (in rad/s) indicates the occurence of a recirculation.

  4. Vector complexity

    Time frame: 6 to 8 weeks after the procedure (endovascular repair)

    The second blood flow parameters derived from the echoPIV data is the vector complexity. Vector complexity is a measure of multi-directional flow, ranging from 0 till 1. a value of 1 means complex flow with all velocity vectors pointing in all directions, whereas a value of 0 means laminar flow with all velocity vectors pointing in the same direction. This measure can potentially be used to indicate regions with disturbed blood flow.

Sponsors and collaborators

Lead sponsor

Rijnstate Hospital

Other

Collaborators

  • University of Twente

Registry information

Official study title

Feasibility of Ultrasound Particle Image Velocimetry to Quantify Flow in the Abdominal Aorta Before and After Endovascular Aneurysm Repair

Acronym: EchoPIV in AAA

Important dates

Study start
2022
Primary completion
2023
Study completion
2023
First posted
Dec 8, 2021
Registry last updated
Nov 21, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.